Regulatory News

• Why the Research-Chemical Gray Market Is Not Going Away (And What to Do About It)

  The April 15 reclassification cleared the prescription path for peptides. It did nothing to address the research-chemical channel — which is more dangerous now.

  Apr 26, 2026

• What the July 23–24 PCAC Meeting Will Actually Decide

  The July PCAC meeting will determine final 503A Bulks List placement for the twelve reclassified peptides. The three possible outcomes and what each means.

  Apr 25, 2026

• FDA Removes 12 Therapeutic Peptides From Category 2 — What the April 15 Action Means

  The FDA's April 15 reclassification opens a legal compounding path for BPC-157, TB-500, and 10 other peptides. What it does — and doesn't — change.

  Apr 23, 2026